株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

持続式血糖モニタリング (CGM) 装置の世界市場 - 分析と予測 (2016〜2022年):エンドユーザー集団・コンポーネント・用途別の詳細分析

Global Continuous Glucose Monitoring (CGM) System Market - Analysis & Forecast 2016-2022: Focus on End User Group, Components & Applications

発行 BIS Research 商品コード 408670
出版日 ページ情報 英文 190 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.53円で換算しております。
Back to Top
持続式血糖モニタリング (CGM) 装置の世界市場 - 分析と予測 (2016〜2022年):エンドユーザー集団・コンポーネント・用途別の詳細分析 Global Continuous Glucose Monitoring (CGM) System Market - Analysis & Forecast 2016-2022: Focus on End User Group, Components & Applications
出版日: 2016年12月14日 ページ情報: 英文 190 Pages
概要

当レポートでは、世界の持続式血糖モニタリング (CGM) 装置市場について分析し、市場の背景事情や主な市場促進・抑制要因、市場全体およびエンドユーザー集団別・コンポーネント別・用途別・地域別の動向見通し (今後7年間分)、昨今の市場競争・資本取引の動き、主要企業のプロファイルなどについて調査しております。

エグゼクティブ・サマリー

第1章 分析範囲・手法

第2章 市場のダイナミクス

  • 市場促進要因
    • 糖尿病患者の増加
    • 治療を受ける患者の増加
    • スマートフォン・ウェアラブル機器の医療分野への浸透
    • 肥満人口の増加
    • 健康保険・医療費償還制度
  • 市場の課題
    • 厳格な規制・規格
    • 多大な時間・訓練の必要性
    • 装置価格の高さ
  • 市場機会
    • 人工腎臓の進歩
    • 非侵襲的血糖モニタリング装置の開発

第3章 競争分析

  • 市場の主な動向と戦略
    • 製品開発・発売
    • 事業協力・合弁事業・事業提携
    • 事業拡張・契約
    • 特許・認可・認証
    • 企業合併・買収 (M&A)
    • その他
  • 業界の求心力

第4章 産業分析

  • 特許分析
  • 企業連合・業界団体・監督官庁
  • バリューチェーン分析

第5章 世界の持続式血糖モニタリング (CGM) 装置市場の分析と予測

  • 前提条件
  • 市場概要
    • 糖尿病の種類
      • 1型糖尿病
      • 2型糖尿病
      • 妊娠糖尿病
    • CGM装置の新たな技術と傾向
  • 世界のCGM装置市場:エンドユーザー別
    • 児童・青少年
    • 青年
    • 中年・高齢者
  • 世界のCGM装置市場:コンポーネント別
    • インスリンポンプ
    • センサー
    • 送信器・受信器
  • 世界のCGM装置市場:用途別
    • 在宅治療用
    • 病院
    • クリニック・診断センター
  • 世界のCGM装置市場:地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 他の国々 (RoW)

第6章 企業プロファイル

  • Abbott
    • 企業概要
    • 財務状況
      • 財務概要
    • SWOT分析
  • AstraZeneca
  • Bayer Healthcare AG
  • Becton Dickinson & Co.
  • Dexcom, Inc.
  • Eli Lilly and Company
  • Johnson & Johnson
  • Medtronic Incorporation
  • Novo Nordisk
  • Roche
  • Sanofi Pharma
  • Tandem Diabetes Care, Inc.
  • Ypsomed
  • その他の有力企業の概略
    • Julphar Diabetes
    • GlySens
    • Glucovation
    • Nova Biomedical
    • Ascensia Diabetes Care
    • Echo Therapeutics
    • Insulet Corporation
    • オムロン ヘルスケア
    • A. Menarini Diagnostics
    • Arkray Inc.

図表一覧

目次
Product Code: BH012A

The global Continuous Glucose Monitoring (CGM) Systems market has been identified as one of the fastest growing industries, owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among a plethora of public companies.

The gradual advancement and innovation of new diabetic care technologies have formed a concrete platform for the further growth of Continuous Glucose Monitoring (CGM) Systems market. With the emergence of advanced technologies such as mobile health, smart sensors, wearable technologies, and 3D-printing into the field of diabetic care, there has been a rise in the overall demand of the newly developed CGM devices.Presently, the focus of the government initiative is mainly towards developing non-invasive solutions, controlling the level of increase in diabetic population, and integrating advanced technologies to fulfill the unmet needs of the diabetic population.

Governmental regulations and standards are playing a major role in sustaining the growth and development of the CGM Systems market. The main aim of these regulations is to make the device more adaptable and attentive towards different types of diabetic conditions as well as to provide modern mobile technologies to the diabetic population.The patients benefit indirectly through these regulations as it helps them to save time and cuts-down the overall cost of monitoring devices as the patients receive the required treatment for the disease.

The market growth is propelled due to factors such as: increasing demand for non-invasive treatments, technological innovation and advancements, increasing diabetic population, and Medicare& reimbursement policies, among others.

This study includes an overview and analysis of the CGM Systems market, by components end user groups, applications, and geography, allowing the research to develop a comprehensive outlook of the market. The market report presents a detailed and analytical studyof the entire market and provides a comprehensive insight into various forms of developments, trends and key participants. The type of diabetes are categorized into three major categories, viz. type 1, type 2, and gestational in the report. All of the above mentioned report coverage parameters are discussed across different regions such as North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, associations, and regulatory bodies, and their involvement in the CGM Systems market.

The answers to the following key questions can be found in the report:

  • What are the major drivers, challenges and opportunities of the CGM Systems market and their use cases?
  • How is the blood glucose monitoring device market evolving?
  • What are the driving and restraining factors in the blood glucose monitoring device market?
  • What are the market shares of the leading segments of the CGM Systems market in 2015?
  • How will each component of the CGM Systems grow over the forecast period and how much revenue will these account for in 2022?
  • How will the market shares of the leading national markets change by 2022 and which country will lead the market in 2022?
  • How the industry will evolve during the period between 2016 and 2022?
  • What are the key developmental strategies implemented in different applications across all regions?
  • How will the key market players leverage on key developments such as mergers & acquisitions, partnerships, and product launches among others?
  • Which geographical region will lead the global CGM Systems market by the end of the forecast period?
  • Who are the key players in the CGM Systems market?
  • What are different end user groups in this market and how are they categorized?
  • What are the different applications in which CGM devices are being used?
  • What are the different used case scenarios considered under different applications?
  • What are the market trends and key developments in different geographical regions?

The research study tries to answer various aspects of the CGM Systemsmarket with the help of central factors driving the market, threats that can possibly slow down the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study takes into account Porter's Five Force model and opportunity matrix for an in-depth study of the CGM Systems market and an assessment of the factors governing the same.

Table of Contents

Executive Summary

1. The Research Scope and Methodology

  • 1.1. Scope of the Report
  • 1.2. Global Continuous Glucose Monitoring (CGM) Systems Market Research Methodology

2. Market Dynamics

  • 2.1. Market Drivers
    • 2.1.1. High Prevalence of Diabetic Population
    • 2.1.2. Patients Involvement in Healthcare
    • 2.1.3. Proliferation of Smartphones and Wearable Devices into Healthcare
    • 2.1.4. Prevalence of Overweight and Obesity in Selected Countries
    • 2.1.5. Medicare and Reimbursements
  • 2.2. Market Challenges
    • 2.2.1. Stringent Regulations and Standards
    • 2.2.2. Requirement of Enormous Time and Training by Patients
    • 2.2.3. High Cost of Device
  • 2.3. Market Opportunities
    • 2.3.1. Evolution of Artificial Pancreas
    • 2.3.2. Innovation of Non-Invasive Glucose Monitoring Devices

3. Competitive Insights

  • 3.1. Key Market Developments & Strategies
    • 3.1.1. Product Launch and Development
    • 3.1.2. Collaborations, Joint Ventures & Partnerships
    • 3.1.3. Business Expansion and Contracts
    • 3.1.4. Patent, Approvals and Certifications
    • 3.1.5. Mergers and Acquisitions
    • 3.1.6. Other Strategies
  • 3.2. Industry Attractiveness

4. Industry Analysis

  • 4.1. Patent Analysis
  • 4.2. Consortium, Association and Regulatory Bodies
  • 4.3. Value Chain Analysis

5. The Global CGM Systems Market Analysis & Forecast

  • 5.1. Assumptions for Analysis and Forecast of the Global CGM Systems Market
  • 5.2. Market Overview
    • 5.2.1. Type of Diabetes
      • 5.2.1.1. Type 1 Diabetes
      • 5.2.1.2. Type 2 Diabetes
      • 5.2.1.3. Gestational Diabetes
    • 5.2.2. Emerging Technologies & Trends in CGM Systems
  • 5.3. Global Continuous Glucose Monitoring (CGM) System Market by End User Group
    • 5.3.1. Children and Teens
    • 5.3.2. Youth
    • 5.3.3. Middle Elderly and Aged
  • 5.4. Global Continuous Glucose Monitoring (CGM) System Market by Components
    • 5.4.1. Insulin Pumps
    • 5.4.2. Sensors
    • 5.4.3. Transmitters & Receivers
  • 5.5. Global Continuous Glucose Monitoring (CGM) Systems Market by Applications
    • 5.5.1. Households/Home Setting
    • 5.5.2. Hospitals
    • 5.5.3. Clinics & Diagnosis Centres
  • 5.6. Global Continuous Glucose Monitoring (CGM) Systems Market by Geography
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. APAC
    • 5.6.4. Rest of the World (ROW)

6. Company Profiles

  • 6.1. Abbott
    • 6.1.1. Company Overview
    • 6.1.2. Financials
      • 6.1.2.1. Financial Summar
    • 6.1.3. SWOT Analysis
  • 6.2. AstraZeneca
    • 6.2.1. Company Overview
    • 6.2.2. Financials
      • 6.2.2.1. Financial Summary
    • 6.2.3. SWOT Analysis
  • 6.3. Bayer Healthcare AG
    • 6.3.1. Company Overview
    • 6.3.2. Financials
      • 6.3.2.1. Financial Summary
    • 6.3.3. SWOT Analysis
  • 6.4. Becton Dickinson & Co.
    • 6.4.1. Company Overview
    • 6.4.2. Financials
      • 6.4.2.1. Financial Summary
    • 6.4.3. SWOT Analysis
  • 6.5. Dexcom, Inc.
    • 6.5.1. Company Overview
    • 6.5.2. Financials
      • 6.5.2.1. Financial Summary
    • 6.5.3. SWOT Analysis
  • 6.6. Eli Lilly and Company
    • 6.6.1. Company Overview
    • 6.6.2. Financials
      • 6.6.2.1. Financial Summary
    • 6.6.3. SWOT Analysis
  • 6.7. Johnson & Johnson
    • 6.7.1. Company Overview
    • 6.7.2. Financials
      • 6.7.2.1. Financial Summary
    • 6.7.3. SWOT Analysis
  • 6.8. Medtronic Incorporation
    • 6.8.1. Company Overview
    • 6.8.2. Financials
      • 6.8.2.1. Financial Summary
    • 6.8.3. SWOT Analysis
  • 6.9. Novo Nordisk
    • 6.9.1. Company Overview
    • 6.9.2. Financials
      • 6.9.2.1. Financial Summary
    • 6.9.3. SWOT Analysis
  • 6.10. Roche
    • 6.10.1. Company Overview
    • 6.10.2. Financials
      • 6.10.2.1. Financial Summary
    • 6.10.3. SWOT Analysis
  • 6.11. Sanofi Pharma
    • 6.11.1. Company Overview
    • 6.11.2. Financials
      • 6.11.2.1. Financial Summary
    • 6.11.3. SWOT Analysis
  • 6.12. Tandem Diabetes Care, Inc.
    • 6.12.1. Company Overview
    • 6.12.2. Financials
      • 6.12.2.1. Financial Summary
    • 6.12.3. SWOT Analysis
  • 6.13. Ypsomed
    • 6.13.1. Company Overview
    • 6.13.2. Financials
      • 6.13.2.1. Financial Summary
    • 6.13.3. SWOT Analysis
  • 6.14. Snapshot of Other Prominent Players
    • 6.14.1. Julphar Diabetes
    • 6.14.2. GlySens
    • 6.14.3. Glucovation
    • 6.14.4. Nova Biomedical
    • 6.14.5. Ascensia Diabetes Care
    • 6.14.6. Echo Therapeutics
    • 6.14.7. Insulet Corporation
    • 6.14.8. Omron Healthcare
    • 6.14.9. A. Menarini Diagnostics
    • 6.14.10. Arkray Inc.

LIST OF TABLE

  • Table 3.1: Product Launch and Development
  • Table 3.2: Collaborations, Joint Ventures & Partnerships
  • Table 3.3: Business Expansion and Contracts
  • Table 3.4: Patent and Approvals
  • Table 3.5: Mergers and Acquisitions
  • Table 3.6: Others
  • Table 4.1: Example of Some Recent Patents
  • Table 4.2: Example of Some Regulatory Bodies, Associations, & Consortia
  • Table 5.1: Hyperglycemia in Pregnancy in Women aged 20-49 Years by Region, 2015
  • Table 5.2: Number of Diabetic Patients in Major Countries
  • Table 5.3: Global CGM Systems Market Value by End User Group, 2015-2022
  • Table 5.4: Table Global CGM Systems Market Value by Components, 2015-2022
  • Table 5.5: Table Global CGM Systems Market Value by Applications, 2015-2022
  • Table 5.6: Table Global CGM Systems Market Value by Geography, 2015-2022
  • Table 5.7: Diabetes in Americas, 2014 (20-79 Years)
  • Table 5.8: Table North America: CGM Systems market Value by End User Group ($Million), 2015-2022
  • Table 5.9: Diabetes in Europe, 2014 (20-79 Years)
  • Table 5.10: Table Europe: CGM Systems Market Value by End User Group, 2015-2022
  • Table 5.11: Diabetes in APAC, 2014 (20-79 Years)
  • Table 5.12: APAC: CGM Systems Market Value by End User Group ($Million), 2015-2022
  • Table 5.13: Diabetes in Row, 2014 (20-79 Years)
  • Table 5.14: RoW: CGM Systems Market Value by End User Group ($Million), 2015-2022

LIST OF FIGURES

  • Figure 1: Relation between the Total Population and Diabetic Population Worldwide
  • Figure 2: Global CGM Systems Market Trends
  • Figure 3: Global CGM Market Value ($Million) for the Time Period 2015-2022
  • Figure 4: Global CGM Market Value by Components ($Million), 2015-2022
  • Figure 5: Global CGM Market Value by End User Group ($Million), 2015-2022
  • Figure 6: Global CGM Market Value by Applications ($Million), 2015-2022
  • Figure 7: Global CGM Market Value by Geography ($Million), 2015-2022
  • Figure 8: Global CGM Market Scenario, 2015 and 2022
  • Figure 1.1: Global CGM Systems Market Scope
  • Figure 1.2: Secondary Data Sources
  • Figure 1.3: Top Down Approach
  • Figure 1.4: Global CGM Systems Market Influencing Factors
  • Figure 1.5: Assumptions and Limitations
  • Figure 2.1: Global CGM Systems Market: Market Dynamics
  • Figure 2.2: Global CGM Systems Market Drivers
  • Figure 2.3: Obesity Prevalence Rate: Top Five Countries
  • Figure 2.4: Global CGM Systems Market Challenges
  • Figure 2.5: Global CGM Systems Market Opportunities
  • Figure 3.1: Recent Market Development Strategy Snapshot Analysis
  • Figure 3.2: Key Market Developments & Strategies
  • Figure 3.3: Impact of the Porter's Five Forces for the Global CGM Systems Market
  • Figure 4.1: Value Chain Analysis
  • Figure 5.1: Type of Diabetes
  • Figure 5.2: T1D Complications
  • Figure 5.3: Top 10 Countries for Number of Children with type 1 Diabetes (0-14 Years)
  • Figure 5.4: T1D Complications
  • Figure 5.5: Prevalence of Diabetes across Geography
  • Figure 5.6: Top Ten Countries/Territories for Number of Adults with Diabetes (In Million)
  • Figure 5.7: Risk Factors for Diabetic Care
  • Figure 5.8: Continuous Glucose Monitoring (CGM) System Market by End User Group
  • Figure 5.9: Global CGM Systems Market Share by End User Group, 2015 and 2022
  • Figure 5.10: Global CGM Systems Market Value for Children & Teens ($Million), 2015-2022
  • Figure 5.11: Global CGM Systems Market Value for Children & Teens by Geography ($Million), 2015-2022
  • Figure 5.12: Global CGM Systems Market Value for Youth ($Million), 2015-2022
  • Figure 5.13: Global CGM Systems Market Value for Youth by Geography ($Million), 2015-2022
  • Figure 5.14: Global CGM Systems Market Value for Middle Elderly and Aged ($Million), 2015-2022
  • Figure 5.15: Global CGM Systems Market Value for Middle Elderly and Aged by Geography ($Million), 2015-2022
  • Figure 5.16: Continuous Glucose Monitoring (CGM) System Market by Components
  • Figure 5.17: Global CGM Systems Market Share by Components, 2015 and 2022
  • Figure 5.18: Global CGM Insulin Pump Market Value ($Million), 2015-2022
  • Figure 5.19: Global CGM Insulin Pump Market Value by Geography ($Million), 2015-2022
  • Figure 5.20: Types of Sensors
  • Figure 5.21: Global CGM Sensor Market Value ($Million), 2015-2022
  • Figure 5.22: Global CGM Sensor Market Value by Geography ($Million), 2015-2022
  • Figure 5.23: Global CGM Transmitter & Receiver Market Value ($Million), 2015-2022
  • Figure 5.24: Global CGM Transmitter & Receiver Market Value by Geography ($Million), 2015-2022
  • Figure 5.25: Continuous Glucose Monitoring (CGM) Systems Market by Applications
  • Figure 5.26: Global CGM Systems Market Share by Applications, 2015 and 2022
  • Figure 5.27: Global CGM Systems Market Value for Households/Home Setting ($Million), 2015-2022
  • Figure 5.28: Global CGM Systems market Value for Home Setting by Geography ($Million), 2015-2022
  • Figure 5.29: Global CGM Systems Market Value for Hospitals ($Million), 2015-2022
  • Figure 5.30: Global CGM Systems Market Value for Hospitals by Geography ($Million), 2015-2022
  • Figure 5.31: Global CGM Systems Market Value for Clinics & Diagnosis Centres ($Million), 2015-2022
  • Figure 5.32: Global CGM Systems Market Value for Clinics & Diagnosis Centres by Geography ($Million), 2015-2022
  • Figure 5.33: Global CGM Systems Market by Geography
  • Figure 5.34: Growth Trajectory of Global CGM Systems Market
  • Figure 5.35: Opportunity Matrix
  • Figure 5.36: CGM Systems Market Value Snapshot by Geography, 2015 and 2022
  • Figure 5.37: Classification of Medical Devices
  • Figure 5.38: Evolution of FDA Activities and Requirements
  • Figure 5.39: North America: CGM Systems Market Value ($Million), 2015-2022
  • Figure 5.40: North America: CGM Systems Market Value by Country ($Million), 2015-2022
  • Figure 5.41: North America: CGM Systems Market Value by Components ($Million), 2015-2022
  • Figure 5.42: North America: CGM Systems Market Value by End User Group
  • Figure 5.43: North America: CGM Systems Market Value by Applications ($Million), 2015-2022
  • Figure 5.44: Europe: CGM Systems Market Value by Country ($Million), 2015-2022
  • Figure 5.45: Europe: CGM Systems Market Value by Components ($Million), 2015-2022
  • Figure 5.46: Europe: CGM Systems Market Value by End User Group
  • Figure 5.47: Europe: CGM Systems Market Value by Applications ($Million), 2015-2022
  • Figure 5.48: APAC: CGM Systems Market Value by Country ($Million), 2015-2022
  • Figure 5.49: APAC: CGM Systems Market Value by Components ($Million), 2015-2022
  • Figure 5.50: APAC: CGM Systems Market Value by End User Group
  • Figure 5.51: APAC: CGM Systems Market Value by Applications ($Million), 2015-2022
  • Figure 5.52: RoW: CGM Systems Market Value by Country ($Million), 2015-2022
  • Figure 5.53: RoW: CGM Systems Market Value by Components ($Million), 2015-2022
  • Figure 5.54: RoW: CGM Systems Market Value by End User Group
  • Figure 5.55: RoW: CGM Systems Market Value by Applications ($Million), 2015-2022
  • Figure 6.1: Abbott: Overall Financials, 2013-2015
  • Figure 6.2: Abbott: Revenue across Different Geographies, 2013-2015
  • Figure 6.3: Abbott: Net Revenue by Business Segment, 2013-2015
  • Figure 6.4: Abbott: SWOT Analysis
  • Figure 6.5: AstraZeneca: Overall Financials, 2013-2015
  • Figure 6.6: AstraZeneca: Revenue across Different Geographies, 2013-2015
  • Figure 6.7: AstraZeneca: SWOT Analysis
  • Figure 6.8: Bayer Healthcare AG: Overall Financials, 2013-2015
  • Figure 6.9: Bayer: Revenue across Different Geographies, 2013-2015
  • Figure 6.10: Bayer: Net Revenue by Business Segment, 2013-2015
  • Figure 6.11: Bayer: SWOT Analysis
  • Figure 6.12: BD & Co.: Overall Financials, 2013-2015
  • Figure 6.13: BD & Co.: Revenue across Different Geographies, 2013-2015
  • Figure 6.14: BD & Co.: Net Revenue by Business Segment, 2013-2015
  • Figure 6.15: BD & Co.: SWOT Analysis
  • Figure 6.16: Dexcom: Overall Financials, 2013-2015
  • Figure 6.17: Dexcom: SWOT Analysis
  • Figure 6.18: Eli Lilly: Overall Financials, 2013-2015
  • Figure 6.19: Eli Lilly: Revenue across different Geographies, 2013-2015
  • Figure 6.20: Eli Lilly: Net Revenue by Business Segment, 2013-2015
  • Figure 6.21: Eli Lilly: SWOT Analysis
  • Figure 6.22: Johnson & Johnson: Overall Financials, 2013-2015
  • Figure 6.23: Johnson & Johnson: Revenue across different Geographies, 2013-2015
  • Figure 6.24: Johnson & Johnson: Net Revenue by Business Segment, 2013-2015
  • Figure 6.25: Johnson & Johnson: Net Revenue by Sub-Business Segment, 2013-2015
  • Figure 6.26: Johnson & Johnson: SWOT Analysis
  • Figure 6.27: Medtronic: Overall Financials, 2013-2015
  • Figure 6.28: Medtronic: Revenue across Different Geographies, 2013-2015
  • Figure 6.29: Medtronic: Net Revenue by Business Segment, 2013-2014
  • Figure 6.30: Medtronic: Net Revenue by Business Segment, 2015
  • Figure 6.31: Medtronic: SWOT Analysis
  • Figure 6.32: Novo Nordisk: Overall Financials, 2013-2015
  • Figure 6.33: Novo Nordisk: Revenue across Different Geographies, 2013-2015
  • Figure 6.34: Novo Nordisk: Net Revenue by Business Segment, 2013-2015
  • Figure 6.35: Novo Nordisk: SWOT Analysis
  • Figure 6.36: Roche: Overall Financials, 2013-2015
  • Figure 6.37: Roche: Revenue across Different Geographies, 2013-2015
  • Figure 6.38: Roche: Net Revenue by Business Segment, 2013-2015
  • Figure 6.39: Roche: SWOT Analysis
  • Figure 6.40: Sanofi: Overall Financials, 2013-2015
  • Figure 6.41: Sanofi: Revenue across Different Geographies, 2013-2015
  • Figure 6.42: Sanofi: Net Revenue by Business Segment, 2013-2015
  • Figure 6.43: Sanofi: SWOT Analysis
  • Figure 6.44: Tandem Diabetic Care, Inc.: Overall Financials, 2013-2015
  • Figure 6.45: Tandem: SWOT Analysis
  • Figure 6.46: Ypsomed: Overall Financials, 2013-2015
  • Figure 6.47: Ypsomed: Revenue across Different Geographies, 2013-2015
  • Figure 6.48: Ypsomed: Net Revenue by Business Segment, 2013-2015
  • Figure 6.49: Ypsomed: SWOT Analysis
Back to Top